Table of Content

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Respiratory Infections?
  • 2.2. The Role of Diagnosis & Treatment
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Distributor and Reagent Supplier
    • 3.1.5. Independent Testing Lab
    • 3.1.6. Public National/regional lab
    • 3.1.7. Hospital lab
    • 3.1.8. Physician Office Labs
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body
  • 3.2. Respiratory Infections
    • 3.2.1. Upper vs. Lower - Marketing Implications
    • 3.2.2. Understanding the Role of Pneumonia
    • 3.2.3. Bacterial Infections
      • 3.2.3.1. Streptococcal Infections
      • 3.2.3.2. Acute Otitis Media
      • 3.2.3.3. Bacterial Rhinosinusitis
      • 3.2.3.4. Diphtheria
      • 3.2.3.5. Pneumococcal Pneumonia
      • 3.2.3.6. Haemophilus Pneumonia
      • 3.2.3.7. Mycoplasma Pneumonia (Walking Pneumonia)
      • 3.2.3.8. Chlamydial Pneumonias and Psittacosis
      • 3.2.3.9. Health Care-Associated Pneumonia
      • 3.2.3.10. Pseudomonas Pneumonia
      • 3.2.3.11. Legionnaires Disease
    • 3.2.4. Tuberculosis - A Special Case
    • 3.2.5. Viral Infections
      • 3.2.5.1. The Common Cold
      • 3.2.5.2. Influenza
      • 3.2.5.3. Viral Pneumonia
      • 3.2.5.4. SARS and MERS
      • 3.2.5.5. Measles (Rubeola)
      • 3.2.5.6. Rubella (German Measles)
      • 3.2.5.7. Chickenpox and Shingles
    • 3.2.6. Fungal and Other Pathogens
      • 3.2.6.1. Histoplasmosis
      • 3.2.6.2. Coccidioidomycosis
      • 3.2.6.3. Blastomycosis
      • 3.2.6.4. Mucormycosis
      • 3.2.6.5. Aspergillosis
      • 3.2.6.6. Pneumocystis Pneumonia
      • 3.2.6.7. Cryptococcosis
  • 3.3. Diagnostics - A Changing Role
    • 3.3.1. Historical Practice
    • 3.3.2. Current Diagnostics
    • 3.3.3. The Multiplex Vector
    • 3.3.4. Future Diagnostics - The Question of When and Where
    • 3.3.5. Respiratory Infection Diagnostics - The Destination
    • 3.3.6. Diagnostics as Defensive Weapons
  • 3.4. COVID-19
    • 3.4.1. Signs and symptoms
    • 3.4.2. Transmission
    • 3.4.3. Diagnosis
    • 3.4.4. Prevention
    • 3.4.5. Management
    • 3.4.6. Prognosis
  • 3.5. Pandemic Diagnostics
    • 3.5.1. Risk Management - Spark and Spread
    • 3.5.2. Dx Technology - Nucleic Acid Based
    • 3.5.3. Dx Technology - Immunoassay & Serology
    • 3.5.4. Time to Market and Preparedness Issues
    • 3.5.5. Unrecognized Role of Multiplex in Pandemic Mangement

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Syndromic Multiplexing
    • 4.1.2. T.A.T.
    • 4.1.3. Antimicrobial Resistance Movement
    • 4.1.4. Pandemic Mitigation
    • 4.1.5. An Aging at Risk Population
  • 4.2. Factors Limiting Growth
    • 4.2.1. The Cost Curve
    • 4.2.2. Regulation and coverage
    • 4.2.3. Laissez Faire
  • 4.3. Instrumentation and Automation
    • 4.3.1. The Shrinking Multiplexing Machine
    • 4.3.2. Bioinformatics Networking and Anonymous Reporting
  • 4.4. Diagnostic Technology Development
    • 4.4.1. The Key Role of Time to Result
    • 4.4.2. Single Cell Genomics Changes the Picture
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. Pathogen Identification - A Projected Timetable of the Future

5. Respiratory Infection Diagnostics Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Genomtec Gets CE-IVD Mark for POC Respiratory Disease Test
  • 5.3. FDA Issues First EUA for Non-Prescription COVID-19/Flu/RSV Test
  • 5.4. "Diagnostics for the Real World" Plans Third-Generation POC Platform
  • 5.5. Cue Health Targets DTC Market
  • 5.6. Investors Skeptical of Ortho Clinical Diagnostics Acquisition by Quidel
  • 5.7. Sense Biodetection to Debut Instrument-Free POC MDx
  • 5.8. LGC Develops 'Ultra-High-Throughput' COVID Workflow
  • 5.9. Cue Health Files for IPO for up to $100M
  • 5.10. QuantuMDx Developing Multiplex System, Syndromic Panels
  • 5.11. Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit
  • 5.12. BforCure Preparing Multiple Panels for PoC qPCR Platform
  • 5.13. Angstrom Bio Raises $3M in Private Financing
  • 5.14. Test for Them All
  • 5.15. Hologic Banking on MDx Acquisitions
  • 5.16. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 5.17. Talis Biomedical 2020 Revenues Rise Sharply
  • 5.18. Luminex to Develop Covid/Flu/RSV Test
  • 5.19. Becton Dickinson Charts Transition of COVID Diagnostics
  • 5.20. MiRxes Receives Approval for Multiplex Covid/Flu Test
  • 5.21. New Silicon-Based Test for Infectious Disease Screening
  • 5.22. GenMark to Meet Demand for Respiratory Panel
  • 5.23. Tempus Announces COVID-19 Testing, Data Initiative
  • 5.24. Abacus Diagnostica Readying Multiplex Respiratory Test
  • 5.25. Qiagen Acquires NeuMoDx Molecular
  • 5.26. Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
  • 5.27. Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
  • 5.28. Cepheid Debuts 10-Color Technology With New Tuberculosis Test
  • 5.29. BioMérieux's Pneumonia Panel Could Improve Care
  • 5.30. Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic
  • 5.31. Genetic Signatures Gets CE Mark for C19 Molecular Test
  • 5.32. Qiagen Respiratory Panel with C19 Receives CE Mark
  • 5.33. Lumos Diagnostics Closes $15M Series A Funding
  • 5.34. Fusion Genomics to Assess NGS Respiratory Tract Assay
  • 5.35. C19 Test Development by Co-Diagnostics
  • 5.36. Rapid Diagnostics Completes Purchase of Enigma Diagnostics
  • 5.37. Flu-Like Epidemic Could Kill 80 Mn Globally
  • 5.38. Startup developing AI for TB detection
  • 5.39. Nipah Virus a Global Threat

6. Profiles of Key Players

  • 6.1. Abacus Diagnostica
  • 6.2. Abbott Laboratories
  • 6.3. Accelerate Diagnostics
  • 6.4. Access Bio
  • 6.5. Ador Diagnostics
  • 6.6. ADT Biotech
  • 6.7. Akonni Biosystems
  • 6.8. Altona Diagnostics
  • 6.9. Alveo Technologies
  • 6.10. Anatolia Geneworks
  • 6.11. Antelope Dx
  • 6.12. Applied BioCode
  • 6.13. Assurance Scientific Laboratories
  • 6.14. Aureum Diagnostics
  • 6.15. Aus Diagnostics
  • 6.16. Beckman Coulter Diagnostics
  • 6.17. Becton, Dickinson and Company
  • 6.18. Binx Health
  • 6.19. Biocartis
  • 6.20. BioFire Diagnostics (bioMérieux)
  • 6.21. bioMérieux Diagnostics
  • 6.22. Bio-Rad Laboratories, Inc.
  • 6.23. Bosch Healthcare Solutions GmbH
  • 6.24. Celemics
  • 6.25. Cepheid (Danaher)
  • 6.26. Chembio
  • 6.27. Co Diagnostics
  • 6.28. Credo Diagnostics Biomedical
  • 6.29. Cue Health
  • 6.30. Curetis N.V. / Curetis GmbH
  • 6.31. Detect
  • 6.32. Diagenode Diagnostics
  • 6.33. Diascopic
  • 6.34. Diasorin S.p.A.
  • 6.35. Enzo Biochem
  • 6.36. Eurofins Scientific
  • 6.37. Fluxergy
  • 6.38. Fulgent Genetics
  • 6.39. Fusion Genomics.
  • 6.40. Genetic Signatures
  • 6.41. GenMark Dx (Roche)
  • 6.42. Hibergene Diagnostics
  • 6.43. Hologic
  • 6.44. Immunexpress
  • 6.45. Inflammatix
  • 6.46. Invetech
  • 6.47. Janssen Diagnostics
  • 6.48. Karius
  • 6.49. Lexagene
  • 6.50. LightDeck Diagnostics
  • 6.51. Luminex Corp
  • 6.52. Lumos Diagnostics
  • 6.53. Mammoth Biosciences
  • 6.54. Maxim Biomedical
  • 6.55. Meridian Bioscience
  • 6.56. Mesa Biotech (Thermo Fisher)
  • 6.57. Millipore Sigma
  • 6.58. Mindray
  • 6.59. Mobidiag (Hologic)
  • 6.60. Mologic
  • 6.61. Nanomix
  • 6.62. Operon
  • 6.63. Oxford Nanopore Technologies
  • 6.64. Panagene
  • 6.65. Perkin Elmer
  • 6.66. Prenetics
  • 6.67. Primerdesign (Novacyt)
  • 6.68. Prominex
  • 6.69. Qiagen
  • 6.70. QuantuMDx
  • 6.71. Quidel
  • 6.72. Roche Molecular Diagnostics
  • 6.73. Seegene
  • 6.74. Siemens Healthineers
  • 6.75. Sona Nanotech
  • 6.76. SpeeDx
  • 6.77. T2 Biosystems
  • 6.78. Talis Biomedical
  • 6.79. Thermo Fisher Scientific Inc.
  • 6.80. Veramarx
  • 6.81. Veredus Laboratories
  • 6.82. Visby Medical
  • 6.84. XCR Diagnostics
  • 6.85. Zhejiang Orient Gene Biotech

7. The Global Market for Respiratory Infection Diagnostics

  • 7.1. Global Market by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Technology - Overview
    • 7.2.1. Table - Global Market by Technology
    • 7.2.2. Chart - Global Market by Technology - Base/End Year Comparison
    • 7.2.3. Chart - Global Market by Technology - Base Year
    • 7.2.4. Chart - Global Market by Technology - End Year
    • 7.2.5. Chart - Global Market by Technology - Share by Year
    • 7.2.6. Chart - Global Market by Technology - Segment Growth
  • 7.3. Global Market by Plex - Overview
    • 7.3.1. Table - Global Market by Plex
    • 7.3.2. Chart - Global Market by Plex - Base/End Year Comparison
    • 7.3.3. Chart - Global Market by Plex - Base Year
    • 7.3.4. Chart - Global Market by Plex - End Year
    • 7.3.5. Chart - Global Market by Plex - Share by Year
    • 7.3.6. Chart - Global Market by Plex - Segment Growth
  • 7.4. Global Market by Place - Overview
    • 7.4.1. Table - Global Market by Place
    • 7.4.2. Chart - Global Market by Place - Base/End Year Comparison
    • 7.4.3. Chart - Global Market by Place - Base Year
    • 7.4.4. Chart - Global Market by Place - End Year
    • 7.4.5. Chart - Global Market by Place - Share by Year
    • 7.4.6. Chart - Global Market by Place - Segments Growth
  • 7.5. Global Market by Product - Overview
    • 7.5.1. Table - Global Market by Product
    • 7.5.2. Chart - Global Market by Product - Base/End Year Comparison
    • 7.5.3. Chart - Global Market by Product - Base Year
    • 7.5.4. Chart - Global Market by Product - End Year
    • 7.5.5. Chart - Global Market by Product - Share by Year
    • 7.5.6. Chart - Global Market by Product - Segments Growth

8. Global Respiratory Infection Diagnostic Markets - By Technology

  • 8.1. Microbiology
    • 8.1.1. Table Microbiology - by Country
    • 8.1.2. Chart - Microbiology Growth
  • 8.2. PCR
    • 8.2.1. Table PCR - by Country
    • 8.2.2. Chart - PCR Growth
  • 8.3. NGS
    • 8.3.1. Table NGS - by Country
    • 8.3.2. Chart - NGS Growth
  • 8.4. Immunoassay/Other
    • 8.4.1. Table Immunoassay - by Country
    • 8.4.2. Chart - Immunoassay/Other Growth
  • 8.5. C19 Singleplex
    • 8.5.1. Table C19splex - by Country
    • 8.5.2. Chart - C19splex Growth

9. Global Respiratory Infection Diagnostic Markets - by Plex

  • 9.1. C19 Single Plex
    • 9.1.1. Chart - C19 Single Plex Growth
  • 9.2. Singleplex
    • 9.2.1. Table Singleplex - by Country
    • 9.2.2. Chart - Singleplex Growth
  • 9.3. Duplex/Triplex
    • 9.3.1. Table Duplex/Triplex - by Country
    • 9.3.2. Chart - Duplex/Triplex Growth
  • 9.4. Multiplex Technology
    • 9.4.1. Table Multiplex - by Country
    • 9.4.2. Chart - Multiplex Growth

10. Global Respiratory Infection Diagnostic Markets - by Place

  • 10.1. Hospital Lab
    • 10.1.1. Table Hospital Lab - by Country
    • 10.1.2. Chart - Hospital Lab Growth
  • 10.2. Outpatient Lab
    • 10.2.1. Table Outpatient Lab - by Country
    • 10.2.2. Chart - Outpatient Lab Growth
  • 10.3. POC
    • 10.3.1. Table POC - by Country
    • 10.3.2. Chart - POC Growth
  • 10.4. Other Technology
    • 10.4.1. Chart - Other Growth

11. Global Respiratory Infection Diagnostic Markets - by Product

  • 11.1. Instruments
    • 11.1.1. Table Instruments - by Country
    • 11.1.2. Chart - Instruments Growth
  • 11.2. Consumables
    • 11.2.1. Table Consumables - by Country
    • 11.2.2. Chart - Consumables Growth
  • 11.3. Software & Service
    • 11.3.1. Table Software & Service - by Country
    • 11.3.2. Chart - Software & Service Growth

12. Appendices

  • 12.1. United States Medicare System: January 2022 Clinical Laboratory Fees Schedule